0 77

Cited 0 times in

아토피피부염의 치료

Other Titles
 Treatment of Atopic Dermatitis 
 한태영  ;  나찬호  ;  이지현  ;  김혜원  ;  박창욱  ;  서영준  ;  손상욱  ;  신민경  ;  안지영  ;  이양원  ;  장용현  ;  박영립  ;  유박린 
 Korean Journal of Dermatology (대한피부과학회지), Vol.56(10) : 581-593, 2018 
Journal Title
 Korean Journal of Dermatology (대한피부과학회지) 
Issue Date
Atopic dermatitis ; Guideline ; Treatment
Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that affects both children and adults. AD is the cause of considerable morbidity including severe pruritus and impaired quality of life. Treatments for active disease include avoidance of triggering factors, barrier repair, topical medications including topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs), phototherapy, antibacterial agents, and systemic immunosuppressants including cyclosporine. Until recently, the only Food and Drug Administration (FDA)-approved systemic treatment options for patients with moderate-to-severe AD were steroids and cyclosporine. Systemic steroids are not recommended by current guidelines and are commonly associated with disease rebound. Instead, clinicians choose from several off-label immunosuppressants. In 2018, the Korean FDA approved dupilumab for adults with moderate-to-severe AD whose disease is not adequately controlled with topical therapies. The implementation of treatment guidelines for AD is challenging. Herein, we review the several treatment modalities for AD and recommend a treatment algorithm.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
Yonsei Authors
Park, Chang Ook(박창욱) ORCID logo https://orcid.org/0000-0003-3856-1201
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.